Key Benefits of Trajenta 5 mg Tablets

The key benefits of Trajenta 5 mg tablets include:

1. Improved Glycemic Control: Trajenta has been shown to effectively lower HbA1c levels, a key measure of blood glucose control, when used alone or in combination with other diabetes medications like metformin, sulfonylureas, or insulin. 
2. Versatile Treatment Option: Trajenta can be used as monotherapy when metformin is inappropriate, or in combination with other diabetes medications to provide better glycemic control. 
3. Convenient Once-Daily Dosing: The recommended dose of Trajenta is 5 mg taken once daily, which can be taken with or without food. This makes it a convenient treatment option for patients. 
4. No Dose Adjustment Required: Trajenta does not require dose adjustments for patients with renal or hepatic impairment, or based on age. This simplifies treatment management. 

Key Ingredients

The key ingredient in Trajenta 5 mg tablets is:

• Linagliptin – This is the active pharmaceutical ingredient, which belongs to the class of medications known as dipeptidyl peptidase-4 (DPP-4) inhibitors. Linagliptin helps increase insulin production and decrease glucose production, thereby improving glycemic control in patients with type 2 diabetes.

  Mechanism of Action of Trajenta (Linagliptin)

  Trajenta (linagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which is the key mechanism of action underlying its therapeutic effects in type 2 diabetes.Key Points on the Mechanism of Action

  1. DPP-4 Inhibition: Linagliptin binds very effectively and reversibly to the DPP-4 enzyme. This inhibits the breakdown of incretin hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
  2. Increased Incretin Levels: By inhibiting DPP-4, linagliptin leads to a sustained increase and prolongation of active incretin levels in the body.
  3. Improved Glycemic Control: The increased incretin levels stimulate insulin secretion and suppress glucagon secretion in a glucose-dependent manner. This helps to lower blood glucose levels.
  4. Glucose-Dependent Mechanism: The effects of linagliptin on insulin and glucagon secretion are glucose-dependent, meaning they only occur when blood glucose levels are elevated. This reduces the risk of hypoglycemia (low blood sugar).
  

  

  

  

  Linagliptin

  Medication for type 2 diabetes

  More

  Type of Medication

  Dipeptidyl peptidase-4 inhibitor

  Common Side Effects

  Inflammation of the nose and throat, angioedema, pancreatitis, joint pain

  Approval and Availability

  Approved for medical use in the United States, Japan, EU, Canada, and Australia in 2011. Became available as a generic medicine in the US in 2020.

  Chemical Structure of Linagliptin

  The chemical structure of linagliptin, the active ingredient in Trajenta 5 mg tablets, is:Linagliptin chemical structureKey points about the chemical structure:

  • The molecular formula is C25H28N8O2 and the molecular weight is 472.54 g/mol.
  • Linagliptin is a white to yellowish, not or only slightly hygroscopic solid substance.
  • It is very slightly soluble in water (0.9 mg/mL). Linagliptin is soluble in methanol (ca. 60 mg/mL), sparingly soluble in ethanol (ca. 10 mg/mL), very slightly soluble in isopropanol (<1 mg/mL), and very slightly soluble in acetone (ca. 1 mg/mL).
  • The chemical name is 1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-.

  

  

  

  Dosage

  • Recommended Dose: The recommended dose of Trajenta is 5 mg once daily, taken with or without food at any time of the day.
  • Combination Therapy: When used in combination with metformin, the dose of metformin should be maintained, and Trajenta administered concomitantly. For combination with sulphonylurea or insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce the risk of hypoglycemia.

  Storage

  • Special Storage Conditions: Trajenta does not require any special storage conditions. It can be stored at room temperature.

  Reviews

  • General Reviews: Trajenta is generally well-tolerated and effective in improving glycemic control in patients with type 2 diabetes. It is often prescribed when diet and exercise alone or other medicines do not provide adequate control.
  • Common Side Effects: The most common side effects include hypoglycemia, nasopharyngitis, cough, vomiting, diarrhea, and constipation.
  • Patient Feedback: Patients generally report positive experiences with Trajenta, citing its ease of use and effectiveness in managing their blood sugar levels.

  Product Information

  • Product Origin: Trajenta is an imported product.
  • Product Description: Trajenta is a film-coated tablet containing 5 mg of linagliptin. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

  Additional Information

  • Special Populations: No dose adjustment is required for patients with renal impairment or hepatic impairment. No dose adjustment is necessary based on age. The safety and efficacy of Trajenta in children and adolescents have not been established.
  • Method of Administration: The tablets should be swallowed whole and not chewed, crushed, or broken. If a dose is missed, it should be taken as soon as the patient remembers, but not as a double dose.